No Picture
News

Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients

BRUSSELS and SAN DIEGO, Jan. 21, 2019 /PRNewswire/ — The Center for Beta Cell Therapy in Diabetes, coordinator of an international consortium in translational medicine in diabetes, and ViaCyte, Inc., a privately held regenerative medicine company,… […]

No Picture
News

Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results

CUMBERLAND, R.I. and LA JOLLA, Calif., Jan. 16, 2019 /PRNewswire/ — The results of the NT-501 Phase 2 study sponsored by Neurotech Pharmaceuticals, Inc. (Neurotech) in collaboration with the Lowy Medical Research Institute (LMRI), have been publish… […]

No Picture
News

Phoenix Molecular Designs Announces Collaboration To Develop Diagnostic for Triple-Negative Breast Cancer

-Diagnostic can detect activated RSK2, a prime target in TNBC, in breast cancer patients-

VANCOUVER, British Columbia and SAN DIEGO, Jan. 16, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing… […]

No Picture
News

Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor

SAN DIEGO, Jan. 15, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C… […]

No Picture
News

Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference

– Anticipated ENHANZE® Partner Progress in 2019 Includes One FDA Approval, New Regulatory Submissions and a New Phase 3 Initiation- Completed Enrollment in Phase 3 Metastatic Pancreas Cancer Study with Data Projected in Second Half of 2019

SAN DIEGO,… […]

No Picture
News

In Promise of True Liquid Biopsy for Cancer, Chip Company BioFluidica® Awarded $1.7 Million by National Cancer Institute/National Institutes of Health for Clinical Trial in Children with Acute Lymphoblastic Leukemia

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — BioFluidica, a privately held cancer diagnostics company, has been awarded an SBIR Phase II National Institutes of Health grant of $1.7 million for a clinical trial in support of “Increased sensitivity of mini… […]

No Picture
News

Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke

– itMSCs were safe and well tolerated in the study — Results of the study are supportive of advancing clinical program — Plans are underway to conduct Phase IIb trial following consultation with the FDA –

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — Ste… […]

No Picture
News

Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX) a clinical-stage targeted oncology company, today announced a clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of sitravatinib and n… […]

No Picture
News

Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study

No Adverse or Other Significant Findings to Date Across All Dose Groups TestedData Package to Be Submitted to FDA to Support Potential Resumption of Phase 1 Clinical Study

LA JOLLA, Calif., Jan. 4, 2019 /PRNewswire/ — Regulus Therapeutics Inc. (Nasd… […]